NCT01666314View on ClinicalTrials.gov

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

August 20, 2012

Primary Completion Date

September 12, 2013

Study Completion Date

September 1, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Orteronel

Orteronel tablets

DRUG

Orteronel Placebo

Orteronel placebo-matching tablets

DRUG

Prednisone

Prednisone 5 mg

Trial Locations (1)

68130

Urology Cancer Center, PC, Omaha

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01666314 - Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter